CAMBRIDGE, Mass.–(BUSINESS WIRE)–Compass Therapeutics, a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics, today announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Monday, January 13, 2020.
In his presentation, Dr. Schuetz will describe the clinical development strategy and share early clinical data of the company’s lead candidate, CTX-471, a fully human agonistic antibody of CD137 now in a Phase 1 study in selected patients with advanced solid tumors. Additionally, Dr. Schuetz will provide an update on CTX-8371, a novel PD-1/PD-L1 bispecific which has shown significantly increased activity compared to approved PD-1/PD-L1 therapies in preclinical testing.
The presentation details are:
Date: Monday, January 13, 2020
Time: 2:30 – 2:55 p.m. PT
Location: Elizabethan C/D, Westin St. Francis
About Compass Therapeutics
Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. Compass is leveraging its proprietary StitchMabsTM and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engaging bispecifics targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass.
Ten Bridge Communications